Global Ophthalmic Drugs Market Size, Share, and COVID-19 Impact Analysis, By Disease (Eye Allergy, Eye Infection, Glaucoma, Retinal disorders, Dry Eye, Other), By Drug Class (Anti-Allergy, Anti-Inflammatory, Antiglaucoma, Anti-VEGF Agents), By Dosage (Eye Solutions, Gels, Capsules, Eye Drops, Ointments), By Administration (Systematic, Topical Local Ocular), By Product (Prescription Drugs, Over-the-Counter-Drugs), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030

Industry: Healthcare

RELEASE DATE Feb 2023
REPORT ID SI1534
PAGES 199
REPORT FORMAT PathSoft

Global Ophthalmic Drugs Market Insights Forecasts to 2030

  • The Ophthalmic Drugs Market Size was valued at USD 39.10 billion in 2021.
  • The Worldwide Market Share is growing at a CAGR of 8.25% from 2022 to 2030
  • The Global Ophthalmic Drugs Market Size is expected to reach USD 66.22 billion by 2030
  • Asia Pacific is expected to grow the fastest during the forecast period.

Ophthalmic Drugs Market

Get more details on this report -

Request Free Sample PDF

The Global Ophthalmic Drugs Market Size is expected to reach USD 66.22 billion by 2030, at a CAGR of 8.25% during the forecast period 2022 to 2030. The demand is expected to increase as a result of rising research and development efforts to create and introduce novel ophthalmic medications, as well as a number of strategic initiatives anticipated by the major players.

 

Market Overview

The formulations known as "ophthalmic medications" are those that are intended to treat eye conditions such age-related macular degeneration, cytomegalovirus (CMV) retinitis, cataract, glaucoma, colour blindness, and diabetic macular edoema. Ophthalmic medications include a variety of formulations that are used to treat conditions like glaucoma, cataracts, colour blindness, and macular degeneration. The market for ophthalmic medications will expand in the upcoming years as a result of ongoing research & development in this area and an increase in the amount of money invested in these endeavours. During the projected time, the genetic population will be an Influential component in this market's expansion. The use of ophthalmic medications in the preventive form for a variety of eye illnesses will also contribute to the market's expansion over the course of the forecast period.

 

Report Coverage

This research report categorizes the market for Ophthalmic Drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Ophthalmic Drugs market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Ophthalmic Drugs market.

 

Global Ophthalmic Drugs Market Report Coverage

Report CoverageDetails
Base Year:2021
Market Size in 2021:USD 39.10 Billion
Forecast Period:2021-2030
Forecast Period 2021-2030 CAGR:8.25%
2030 Value Projection:USD 66.22 Billion
Historical Data for:2017-2020
No. of Pages:199
Tables, Charts & Figures:111
Segments covered:By Disease, By Drug Class, By Dosage, By Administration, By Product, By Region, COVID-19 Impact Analysis
Companies Covered:AbbVie Inc. (Allergen plc.), Alcon Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Generics)
Growth Drivers:The majority of businesses on the market are focusing on offering pharmacological combinations for various eye illnesses.
Pitfalls & Challenges:COVID-19 Empact, Challenge, Future, Growth, & Analysis

Get more details on this report -

Request Free Sample PDF
 

Driving Factors

In most countries around the world, there has been an upsurge in the need for ophthalmic medication in recent years. Preventive medications for eye problems will be introduced as a result of government initiatives to raise knowledge about health care. The majority of businesses on the market are focusing on offering pharmacological combinations for various eye illnesses. Long-term demand for these items is anticipated to increase due to the rise in elderly populations around the world. Age-related macular degeneration is a typical occurrence, and in the years to come, there will be a greater demand for various medications to address these conditions. In the upcoming years, the use of these medications to treat retinal illnesses will contribute to a sizable increase in revenue. The market will expand in the upcoming years as a result of the availability of numerous drugs for the treatment and prevention of glaucoma.

 

Restraining Factors

FDA regulations are strict and demand that medications meet efficiency and safety requirements. In the long run, this serves as a restraint on the market's expansion. The amount of money spent on these drugs decreases in emerging countries. The ophthalmic drug business will suffer as a result of a few countries' poor economic conditions. Some underdeveloped nations are unaware of the market-available prophylactic drugs that can halt the development of future eye disorders. The market's expansion would be hampered by this.

 

Market Segmentation

  • In 2021, anti-VEGF agents segment is dominating the market with the largest market share.

On the basis of drug class, the global ophthalmic drugs market is segmented into anti VEGF, anti allergy, anti-inflammatory, anti-glaucoma, and others. Among these, the anti-VEGF segment is dominating the market with the largest market share. Rising anti-VEGF agent usage and demand, as well as the presence of major market players with extensive product lines, all contribute to the segment's growth.

 

  • In 2021, the retinal disorder segment accounted the largest market share over the forecast period.

The retinal segment holds the largest market share over the forecast period. In the upcoming years, the market expansion will likely be driven by the use of the new medications for retinal illnesses, particularly in light of the COVID-19 pandemic's recent outbreak. After the pandemic, cases of various retinal illnesses surged, and medicine sales also rose dramatically.

 

  • In 2021, the eye drop segment to dominate the market with the highest market share over the forecast period.

On the basis of dosage type, the global ophthalmic drugs market is segmented into Eye Solutions, Gels, Capsules, Eye Drops, Ointments. Among these, the eye drop segment is anticipated to dominate the marker with the highest market share over the forecast period. In several countries, eye drops are being sold more frequently as both a preventive medicine and a treatment for a few illnesses. The availability of cutting-edge technology in the ophthalmic medications' drug delivery system will also contribute to the market's expansion in the ensuing years. The efficiency of medicines can be increased thanks to the nanomicellar technology, which has been developed as a result of ongoing research and development in the sector.

 

  • In 2021, the topical route segment to generate the highest revenue over the predicted time frame.

On the basis of administration, the global ophthalmic drugs market is segmented into systematic, topical, local ocular. Among these, the topical route segment to generate the highest revenue over the predicted timeframe. As more new products are introduced to the market, existing formulas are being replaced, which will accelerate market growth in the years to come. A variety of topical treatments for eye problems are now available on the market thanks to ongoing research and development.

  • In 2021, the prescription drugs is going to dominate the market over the forecast period.

On the basis of product, the global ophthalmic drugs market is segmented into prescription drugs, over the counter drugs. Among these, the prescription drugs segment is going to dominate the market over the forecast period. As these medications provide patients greater efficacy and safety, the market is anticipated to expand positively. The most effective way to treat a variety of problems is using prescription medication. The over-the-counter market is also anticipated to have considerable expansion in the upcoming years due to the availability of numerous patient-accessible, readily administered ophthalmic medications.

 

Regional Segment Analysis of the Ophthalmic Drugs Market

 

Ophthalmic Drugs Market

Get more details on this report -

Request Free Sample PDF
  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America holds the largest market share over the forecast period.

Among all other regions, North America holds the largest market share over the forecast period. In the North American region, there are several market participants, and as people become more aware of the products' accessibility, ophthalmic medicine sales will rise. This area has a top-notch healthcare infrastructure and a high level of consumer awareness. Throughout the projection period, these two variables will be crucial to the market's expansion.

 

Recent Developments

  • In July 2021, Bosch has launched U.S. launch of Biotrue, hydration lubricant eye drops.
  • In May 2022, For the treatment of dry eye illness, Brim Biotechnology Inc. and Ora Inc. have formed a partnership to further the development of the regeneration peptide BRM 421.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Ophthalmic Drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

  • AbbVie Inc. (Allergen plc.)
  • Alcon Inc.
  • Bausch & Lomb Incorporated
  • F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • Novartis AG, Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd. (Actavis Generics)

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Ophthalmic Drugs market based on the below-mentioned segments:

 

Ophthalmic Drugs Market, By Drug Class

  • Anti-Allergy
  • Anti-Inflammatory
  • Antiglaucoma
  • Anti-VEGF Agents

 

Ophthalmic Drugs Market, By Disease

  • Eye Allergy
  • Eye Infection
  • Glaucoma
  • Retinal Disorders
  • Dry Eye
  • Others

 

Ophthalmic Drugs Market, By Dosage

  • Eye Solutions
  • Gels
  • Capsules
  • Eye Drops
  • Ointments

 

Ophthalmic Drugs Market, By Administration

  • Systematic
  • Topical
  • Local Ocular

 

Ophthalmic Drugs Market, By Product

  • Prescription Drugs
  • Over-the-Counter-Drugs

 

Ophthalmic Drugs Market, Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies